- Home
- AKAN vs GCTK Comparison
AKAN vs GCTK Comparison
Compare AKAN & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKAN | GCTK |
|---|---|---|
| Founded | 2021 | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.4M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | AKAN | GCTK |
|---|---|---|
| Price | $55.08 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 3.8M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 31.22 |
| Revenue | N/A | ★ $589,462.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.03 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.42 | $0.09 |
| 52 Week High | $54.64 | $15.90 |
Technical Indicators
Market Signals| Indicator | AKAN | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 97.45 | 44.93 |
| Support Level | $0.98 | $0.64 |
| Resistance Level | N/A | $1.02 |
| Average True Range (ATR) | 8.16 | 0.13 |
| MACD | 5.00 | 0.04 |
| Stochastic Oscillator | 66.84 | 23.08 |
Price Performance
Historical ComparisonAbout AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.